gammaCore SapphireTM CV (nVNS) receives Emergency Use Authorization (EUA) to treat patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow. Learn More $ECOR Answers to military & veterans questions about migraine & cluster headache
https://www.gammacore.com/for-veterans/how-gammacore-works-va/ https://www.gammacore.com/for-veterans/testimonials-va/ https://www.gammacore.com/for-veterans/faq/ http://www.electrocore.com/aboutus/ http://www.electrocore.com/nVNS/ http://www.electrocore.com/product/ http://www.electrocore.com/future-developments/ http://www.electrocore.com/for-payers/ News Releases
gammaCore SapphireTM CV (nVNS) receives Emergency Use Authorization (EUA) to treat patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow. Learn More Emergency Use Authorization (EUA)gammaCore SapphireTM CV (nVNS)
receives EUA to treat patients with known or suspected COVID-19
who are experiencing exacerbation of asthma-related dyspnea and reduced airflow.
https://finviz.com/quote.ashx?t=ECOR [-chart]finviz.com/chart.ashx?t=ECOR&ty=c&ta=1&p=d&s=l[/chart]
$ECOR
https://www.otcmarkets.com/stock/ECOR/disclosure https://www.otcmarkets.com/stock/ECOR/news https://www.otcmarkets.com/stock/ECOR/security https://www.otcmarkets.com/stock/ECOR/profile https://www.otcmarkets.com/stock/ECOR/quote https://www.otcmarkets.com/stock/ECOR/overview electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a
range of patient administered non-invasive vagus nerve stimulation (nVNS) therapies.
The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated
with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire,
a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis.
The company was founded in 2005 and is headquartered in Basking Ridge, New Jersey. |
 |
| Period End Date | | TTM | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | | Period Length | | 12 Months | 12 Months | 12 Months | 12 Months | 12 Months | | Total Revenue | | 3.24 | 2.39 | 0.99 | | | Cost of Revenue | | 1.31 | 1.16 | 0.58 | | Gross Profit | | 1.93 | 1.23 | 0.41 | | Selling, General and Administrative | | 23.69 | 35.42 | 42.50 | | Research and Development | | 4.81 | 9.90 | 12.47 | | Unusual Expense/Income | | 0.46 | 2.00 | 0.00 | | Total Operating Expense | | 30.27 | 48.48 | 55.55 | | Operating Income | | -27.03 | -46.09 | -54.55 | | Interest Income Net | | 0.20 | 0.97 | 1.01 | | Other Income Net | | -0.01 | -0.01 | -2.22 | | Net Income Before Taxes | | -26.84 | -45.13 | -55.76 | | Provision for Income Taxes | | -1.15 | 0.02 | 0.00 | | Net Income | | -25.69 | -45.15 | -55.82 | | Income Avail. to Common Excl. Extraord. | | -25.69 | -45.15 | -55.82 | | Income Avail. to Common Incl. Extraord. | | -25.69 | -45.15 | -55.82 | | Diluted Average Shares | | 34.99 | 29.38 | 29.26 | | Diluted EPS Excl. Extraord. | | -0.78660 | -1.53669 | -1.90761 | | Diluted EPS Incl. Extraord. | | -0.78660 | -1.53669 | -1.9076 | |
*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security. what private placement about ????? i see insider buying
https://finviz.com/quote.ashx?t=ecor&ty=c&ta=1&p=d
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Errico Thomas J. Director Apr 14 Buy 0.85 176,470 150,000 1,245,450 Apr 16 09:10 PM
Moody Trevor J Director Apr 14 Buy 0.85 116,647 99,150 177,944 Apr 16 09:09 PM
TULLIS JAMES L L Director Apr 14 Buy 0.85 1,764,705 1,499,999 1,764,705 Apr 16 04:24 PM
These private placement transactions included sales to certain affiliates and existing shareholders of the Company, including some members of the Company’s board of directors. As of September 30, 2020, the Company had the right to sell under the LPC Purchase Agreement approximately $9.9 million of additional shares of common stock. So discounted shares are being dumped at the market price instant profit for the Gang.. No wonder it cant go up